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a b s t r a c t
The Global Vaccine Action Plan 2011–2020 (GVAP) aims to extend the full benefit of vaccination against
vaccine-preventable diseases to all individuals. More than halfway through the Decade of Vaccines, coun-
tries classified as Middle-Income by the World Bank struggle to achieve several GVAP targets. Countries
transitioning from Gavi, the Vaccine Alliance, represent a key sub-group of Middle Income Countries.
Through a review of available literature on the subject, this study documents the lack of comparative
analyses on immunization system performance in countries transitioning from Gavi support. Despite
increased emphasis on the importance of programmatic sustainability beyond financing through the
Gavi 2016–2020 Strategy and availability of data, existing literature has predominantly documented
challenges related to domestic financing of immunization.
This study complements a review of current literature with an analysis of country assessments con-
ducted by immunization partners since 2011, in an effort to document programmatic challenges related
to decision-making for immunization policy, delivery of services, and access to affordable and timely sup-
ply in Gavi transitioning countries.
In light of the findings, we suggest continued systematic compilation of country performance data
beyond financing to inform policy-making, in particular for: (i) development of a more nuanced theory
of change towards sustainable immunization programmes and (ii) measurement of progress and key
areas for attention and investment.
 2018 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND IGO license. (http://
creativecommons.org/licenses/by-nc-nd/3.0/igo/).
1. Introduction
Over the past decade, Middle Income Countries’ (MICs) access
to vaccines has gained global attention. MICs struggle to achieve
the targets set forward in the Global Vaccine Action Plan 2011–
2020 (GVAP) and most either lack or will soon lose external finan-
cial and technical support [1–3].
As of July 2017, of 109 countries classified as MICs (GNI per cap-
ita between US$ 1006 and US$ 12,235) [4] by the World Bank, 42
receive financial and programmatic support through Gavi, the Vac-
cine Alliance [5]. Nevertheless, 26 of these countries have either
transitioned or will soon transition from Gavi support [6]. As sev-
eral countries with large populations below the poverty level have
achieved middle-income status, MICs are now home to two-thirds
of the world’s poorest people and account for two-thirds of deaths
in children under the age of five [7].
According to the current Gavi transition and eligibility policies,
a country enters a five year ‘transition phase’ when its average GNI
per capita over three years equals or exceeds an eligibility thresh-
old amount (US$1580 since 2015)2 [8]. Post-transition, countries do
not receive further support from Gavi, although they may benefit
from Gavi-comparable vaccine prices as well as limited alternative
support from development partners [9].3 Gavi transitioning coun-
tries represent a key sub-group of MICs where the sustainability of
immunization efforts is at stake.
Since 2011, immunization program assessments (transition
assessments) have been conducted in these countries to identify
challenges to transition. The assessments are led by national
https://doi.org/10.1016/j.vaccine.2018.06.012
0264-410X/ 2018 Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND IGO license. (http://creativecommons.org/licenses/by-nc-nd/3.0/igo/).
⇑ Corresponding author.
E-mail address: cernuschit@who.int (T. Cernuschi).
1 Denotes equal contribution.
2 Of note, this threshold is above the World Bank’s middle income threshold and all
Gavi transitioning countries are thus MICs by definition.
3 Since its inception in 2000, Gavi has had incredible success in increasing and
streamlining donor funding for immunization for target countries. While global
entities, such as WHO and UNICEF, have broader mandates encompassing all member
states, they have struggled to continue resourcing for country support activities
beyond the Gavi eligible countries.
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immunization programs with support from Gavi [10]. Following
assessments, Gavi supports the country in developing a transition
plan, consisting of short- to medium-term investments by the gov-
ernment and Gavi to address potential sustainability issues.
To date, results of these transition assessments and plans have
not been systematically compiled and analysed for cross-country
comparison, and existing literature on programmatic immuniza-
tion challenges affecting transitioning countries is limited. This
study aims to document and begin addressing this gap in order
to inform policy-making for sustainable immunization
programmes.
2. Methodology
2.1. Literature review
A systematic literature review was carried out in May 2016 to
retrieve existing comparative analyses of programmatic perfor-
mance for Gavi transitioning countries, in order to identify com-
monly reported challenges. Two sources of information were
examined: (1) published peer-reviewed articles and (2) Gavi docu-
ments. The peer-reviewed literature search was restricted from
January 2009 to the present, reflecting the time during which tran-
sition policies were designed.
For published literature, the following search strategy was
employed in PubMed: (sustainab* OR challenges) AND (immuniza-
tion OR vaccin*) AND (Gavi) AND (graduat* OR transition* OR mid-
dle income). Articles meeting the following criteria were included:
 Discussion of Gavi transition or graduation policies and the
resulting impact on transitioning countries;
 Focus on one or more specific challenge areas (e.g. financing,
supply chain, health workforce) in transitioning, lower-
middle, and middle-income countries;
 Focus on the progression or transition of lower-middle and/or
middle-income countries in developing sustainable and inde-
pendent immunization programmes;
 Reference documents guiding the formation and progress of the
graduation and transition programmes).
Articles in languages other than English, focussing on public
health issues other than immunization, discussing immunization
broadly without focussing on transition, and/or looking at a single
vaccine-preventable disease were instead excluded.
Gavi documents were retrieved from the Gavi Programme and
Policy Committee (PPC) webpage and WHO archives [11]. For the
period of January 2009 to May 2016, the Committee minutes and
Gavi Board meeting agendas were searched for the words ‘‘eligibil-
ity”, ‘‘transition”, and ‘‘graduation,” and matching background and
supporting documents were retrieved from WHO archives. Rele-
vant transition-related policies were additionally extracted from
the library of policies on Gavi’s webpage (2009–2015) [12].
Fig. 1 illustrates the selection process and distribution of docu-
ments. Noting the estimated equivalence in quality, high variation
in focus, and overall low number of peer-reviewed and Gavi docu-
ments retained for analysis, the articles were considered equally in
the assessment. Findings were independently extracted from each
document and compared, to generate a consensus on availability of
information.
2.2. Analysis of country assessments and plans
As a second step, all Gavi transition assessments (15), transition
plans (13) available to WHO as of May 2016 were reviewed. Assess-
ments and plans were retrieved from the Expanded Programme on
Immunization Team (EPI) in theWHO Immunization, Vaccines, and
Biologicals Department (IVB). Table 1 provides a list of transition-
ing countries assessed by this study.
Rather than follow a strictly defined template, assessments are
generated from a high-level guide that is flexibly adapted to each
country’s circumstances. Information gaps were thus anticipated
and addressed with additional sources of information (Table 2).
Transition assessments, transition plans, and supplemental
sources of information were analyzed to understand country pro-
gress towards immunization related targets across four program-
matic areas: (i) decision-making, (ii) political commitment and
financial sustainability, (iii) demand for and equitable delivery of
vaccines, and (iv) access to timely and affordable supply. These
areas represent key pillars of the Immunization Partners’ Shared
Strategy for Sustainable Access to vaccines in MICs, referred to as
the MIC Strategy, endorsed by the WHO Strategic Advisory Group
of Experts in Immunization (SAGE) in April 2015 [3]. While the
MIC Strategy Framework was not developed specifically to analyse
the sustainability of immunization programmes in Gavi transition-
ing countries, the framework was jointly developed by interna-
tional partners and middle-income countries (including several
supported by Gavi), to address concerns of MICs that are financing
immunization efforts with national resources. The Framework thus
provides a reasonable indication of sustainability challenges for
this analysis.
Within this framework, specific indicators and targets were
used to measure performance and challenges in study countries.
In the absence of universally accepted standards, the indicators
and targets used are either commonly accepted (e.g. GVAP targets)
or derived from median values/reported challenges in sample
countries. Basic statistical analysis was performed to determine
the share of Gavi countries meeting, or failing to meet, targets.
Thematic content analysis of qualitative information available in
Fig. 1. Literature review flow diagram.
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transition assessments and plans was further completed following
the MIC Strategy Framework’s programmatic areas. Finally, the ini-
tiatives identified in the plans were matched to needs identified in
the transition assessments.
2.3. Limitations
Several methodological limitations are noteworthy. The study
surveys 15 of 26 Gavi transitioning countries, since transition
assessments were not completed or available at the time of analy-
sis for the remaining 11 countries (India, Lao PDR, Solomon Islands,
Nigeria, Nicaragua, Cuba, Indonesia, Kiribati, Timor-Leste, Vietnam,
Ukraine). Noting that several large countries are excluded, the data
may overlook challenges impacting a significant share of the tran-
sitioning country population.
Moreover, there is currently a lack of consensus within Gavi on
the path to sustainable immunization programs and thus on
related criteria and indicators. While the MIC Strategy and GVAP
provide a useful framework for analysis, the indicators and targets
used in this analysis were not specifically developed to study Gavi
transitioning countries and important considerations may be
overlooked.
Finally, the lack of standardized templates and processes cou-
pled with changing assessment teams impacts the comparability
of assessment data.
These limitations could be addressed as data becomes increas-
ingly available, Gavi develops a more targeted theory of change,
and related monitoring/evaluation frameworks and targeted tools
are developed to assess progress towards sustainability of immu-
nization in transitioning countries.
3. Results
3.1. Literature review
The literature search produced a total of 52 documents, of
which 42 were retained for analysis (see Table S1 for a summary
of results). Gavi documents focus exclusively on transitioning
countries, while peer-reviewed articles include analyses of Gavi-
ineligible MICs. However, both Gavi publications and peer-
reviewed literature focus heavily on appraising financial chal-
lenges for countries [3,9,13–17].
When reviewing the broader performance of immunization
programmes in Gavi transitioning countries, most papers use the
third dose of Diphtheria, Tetanus, and Pertussis (DTP3) immuniza-
tion coverage as a proxy for overall programme impact without
reviewing specific programmatic challenges. There are two excep-
tions: a Gavi document [14] and a peer-reviewed article [16] that
review the transition experience of six countries (Angola, Bhutan,
Republic of Congo, Georgia, Moldova, and Mongolia). Nonetheless,
Table 2
Additional sources of information.
Additional source of information Description Source
Expanded Program on Immunization (EPI) Reviews Comprehensive, periodic evaluations of country EPI programs by
immunization partners
WHO (IVB)
Gavi Annual Program Reviews (APR) and Joint
Appraisals
Annual in-country multi-stakeholder review of the implementation
progress and performance of Gavi grant support to a country [28]
Gavi and WHO (IVB)
Comprehensive Multi-Year Plans (cMYPs) Multi-year strategic plans developed by countries to assess costs of an
immunization programme to meet GVAP goals and mobilize finances [29]
WHO (IVB) and country inquiries)
Effective Vaccine Management (EVM) Assessments Country-generated assessments to monitor and assess supply chain
management [30]
WHO (IVB) and country inquiries
World Development Indicators of the World Bank A collection of national, regional, and global development indicators with
official WB data [4]
World Bank: Online World
Databank
WHO Immunization Repository An online database to manage and review information on new vaccine
introductions, immunization services, and accelerated disease control in
countries
Internal WHO Immunization
Repository
Gavi Country Information A compilation of data on Gavi-eligible and transitioning countries including
basic indicators, a history of Gavi support, financial information, and
coverage data [31]
Online Gavi Country Hub
Table 1
Gavi transitioning countries with available transition assessments.a
Country (WHO) Region Gavi status (2017) Transition plan
1. Angola Africa Accelerated Transition phase 2015–2017
2. Armenia Europe Accelerated transition phase 2014–2015
3. Azerbaijan Europe Accelerated transition phase 2014–2015
4. Bhutan South-East Asia Fully self-financing phase 2015
5. Bolivia Americas Accelerated transition phase 2015–2017
6. Congo Republic Africa Accelerated transition phase 2015–2017
7. Georgia Europe Accelerated transition phase 2015–2017
8. Ghana Africa Accelerated transition phase Not Available
9. Guyana Americas Fully self-financing phase 2015–2017
10. Honduras Americas Fully self-financing phase 2014–2015
11. Moldova Europe Fully self-financing phase 2014–2016
12. Mongolia Western Pacific Fully self-financing phase 2012–2014
13. Papua New Guinea Western Pacific Accelerated transition phase Not Available
14. Sri Lanka South-East Asia Fully self-financing phase 2015
15. Uzbekistan Europe Accelerated transition phase 2014–2015
a As of January 2016.
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while these two articles offer a useful view on country procure-
ment practices, national regulatory authorities and country capac-
ity for immunization planning and advocacy, they provide
examples of issues rather than a comprehensive review of coun-
tries’ challenges. One article elaborating on the rationale for recent
Gavi transition policy updates also provides a high-level discussion
of programmatic challenges [13]. However, aside from a list of
established National Immunization Technical Advisory Bodies
(NITAGs), the article does not provide a comprehensive analysis
beyond financing challenges.
Gavi documents supporting access to Gavi-like prices provide
data on the number of countries with potential payment and pro-
curement inefficiencies and stress vaccine pricing as key factors
affecting countries’ ability to sustainably finance programmes
[9,15].
A more systematic, although limited, analysis of immunization
programmes is provided in an article addressing challenges expe-
rienced by the broader middle-income country group [18]. Here,
Gavi transitioning countries do not receive special attention and
it is thus not possible to identify unique constraints.
Finally, two papers specifically focused on national decision-
making processes provide a review of available information from
country case studies (15 countries) [19] or country interviews
(95 countries) [20] to understand factors affecting decision-
making on new vaccine adoption in low- and middle-income coun-
tries. These papers conclude that the local burden of disease data,
vaccine prices and the cost implications of adopting a new vaccine
are of particular importance in new vaccine adoption decisions in
lower-middle-income countries (LMICs) and that the underlying
driver for vaccine adoption decisions in Gavi-eligible countries
was the desire to seize windows of opportunity for Gavi funding
[19,20].
3.2. Analysis of country assessments and plans
Tables 3–5 provide results of the analysis. The online Appendix
provides further detail.
3.2.1. Decision-making processes
The analysis first examined decision-making processes deter-
mining a country’s capacity to undertake timely and evidence-
based immunization policy and programmatic choices. Effective
immunization decision-making is particularly important for coun-
tries that fully fund immunization programs and thus require
strong evidence to secure sufficient domestic financial resources
while relying less on international recommendations for immu-
nization policies [20]. NITAGs are formal multidisciplinary bodies
of national experts that aim to provide independent, evidence-
based guidance to national policymakers on immunization-
related decisions [21]. WHO recommends the establishment of
NITAGs to enable governments to develop objective policies inde-
pendent of external influence and to improve evidence-based
decision-making on immunization [21]. Although most transition-
ing countries have progressed toward establishing NITAGs in line
with GVAP targets, 60% of the countries under study lack a func-
tional NITAG, particularly African countries [21]. Forty percent of
transition assessments note issues in this area and this issue was
not addressed by transition plans for only 3 countries. Transition
plans generally present two types of support activities in this area:
(a) establishing a NITAG and (b) enhancing access and use of dis-
ease surveillance data to support evidence-based decisions.
3.2.2. Political commitment and financial sustainability
With a loss of financial support from Gavi, transitioning coun-
tries must primarily rely on domestic resources to fund immuniza-
tion services. Thirteen of the fifteen countries under study have a
budget line for immunization as per GVAP recommendations and
62% finance a large portion of both routine immunization and
related vaccines with government sources. Nonetheless, significant
variation exists, with highest coverage in the American region
countries for instance. Nearly half of sample countries have
defaulted at least once on Gavi co-financing requirements, partic-
ularly countries in the African region, and 67% of transition assess-
ments report shortfalls in financing for immunization.
Transition plans largely recognize these well-understood weak-
nesses, recommending the construction of legal frameworks to
ensure the political priority of immunization as well as the devel-
opment of resource mobilization strategies linked to updated
financial projections, cost and economic analyses, and fiscal space
assessments.
3.2.3. Demand for and equitable delivery of vaccines
The analysis of demand for and equitable delivery of vaccines
indicates that only 25% of countries under study have not reported
major data quality issues and that two thirds of countries lack
human resources to adequately provide quality health services,
including immunization. Only 38% of countries have a communica-
tion plan for immunization activities, with the highest investment
in communication noted in the African region. Vaccine manage-
ment is problematic in 60% of countries and, on average, countries
have experienced more than one stock-out per year between 2010
and 2015, with the most concerning results noted in the European
region. Hesitancy among vaccine users is also flagged by most
study countries (92%) and appears to be an important area of
concern.
Transition assessments have identified challenges with data
management, communication, human resources for health and
supply chain in 60, 80, 67 and 80% of countries, respectively. To
address these concerns, transition plans incorporate the following
initiatives: training in data management and use (including sup-
port to implement electronic data systems at the community
level), activities to develop national communication strategies
and targeted media (i.e. posters, radio and television clips), com-
munication training programs for key health officials, and
capacity-building activities to train human resources on cold chain
logistics and basic immunization practices. Overall, 19 of 45 issues
identified across 11 countries are not explicitly addressed by tran-
sition plans.
3.2.4. Access to timely and affordable supply
According to data from the Gavi transition assessments and
from the WHO Regulatory Systems Strengthening team, nearly half
of the study countries utilize a mixed-procurement method to
ensure timely access to affordable supply, procuring Gavi-funded
vaccines and occasionally other routine vaccines through the UNI-
CEF Supply Division (SD).
Transition assessments have evaluated whether countries
procuring partly or fully through the United Nations (UN) can con-
tinue to do so following the termination of Gavi support. Only 4 out
of 14 countries that procure through a UN organization will face
barriers in continuing to use UN procurement due to national leg-
islation requiring local procurement of vaccines.
Transition assessments have also evaluated the capacity of self-
procuring or prospective self-procuring countries. The assessments
report critical self-procurement capacity issues in 7 out of 9 appli-
cable countries. Collectively, across all procurement methods, 73%
of countries under study have identified at least one red flag in
their current procurement practices. Beyond procurement, most
transition assessments also noted barriers to accessing affordable
vaccine pricing.
Transition plans are largely individualized in addressing pro-
curement challenges and include activities such as training on
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procurement methods, improving registration procedures, mid-
level management training, improving the government under-
standing of UNICEF procurement processes, and enabling timely
procurement of traditional and new vaccines.
To conclude, the analysis reviewed the strength of National Reg-
ulatory Authorities (NRAs), which are essential for assuring the
safety, efficacy and quality of vaccines used in national immuniza-
tion programmes [22]. WHO has developed standard criteria for
evaluating NRAs across six key regulatory functions: marketing
authorization and licensing; post-marketing surveillance; NRA lot
release, laboratory access; regulatory inspections; and regulatory
oversight of clinical trials [22]. A review of existing NRA
Table 3
Summary of results.
ii % of countries under study (15).
iii % of countries with available data.
iv WHO JRF asks countries to identify reasons for hesitancy to accept vaccines according to the national schedule. A country identifying 1+ reasons for hesitancy is classified as
having a vaccine hesitancy issue. (See above-mentioned references for further information.)
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assessments concluded that a majority of the study countries do not
have a functional regulatory system. Transition assessments
identified challenges in 53% of countries distributed across all NRA
functions in all regions. Transition plans address country-specific
NRA shortfalls, with a particular focus on strengthening market
authorization and licensing as well as pharmacovigilance, particu-
larly AEFI surveillance. Activities to improve NRA lot release and lab-
oratory access functions are not specifically noted in transition plans.
Nonetheless, the majority of plans calls for the development of blue-
prints for NRA strengthening external to the transition plan. These
activities may thus be described in such NRA-specific documents.
4. Discussion
Through a systematic literature review, this study confirms lim-
ited comparative analyses on immunization system performance
in countries transitioning from Gavi support. Peer-reviewed and
Gavi literature focus primarily on financial challenges. However,
while the ability to sustainably fund immunization programmes
is an area of justified concern, immunization partners have increas-
ingly emphasized the importance of ensuring the programmatic
sustainability of immunization through Gavi’s 2016–2020 Strategy
[23]. Closely monitoring countries’ performance beyond financing
is thus becoming key to informed policy-making, particularly for:
(i) the development of a more nuanced theory of change towards
sustainable immunization programmes; (ii) measurement of pro-
gress and understanding of key areas for attention and for invest-
ment; and (iii) stimulation of further discussion around eligibility
criteria for external support beyond GNI.
Several existing concerns on the programmatic sustainability of
immunization programmes are confirmed by a review of existing
transition assessments and plans and commonly accepted immu-
nization indicators.
4.1. Decision-making processes
The data indicates shortcomings in the use of evidence-based
decision-making in transitioning countries, raising an important
concern as countries lose Gavi support and further rely on autono-
mous decision-making for immunization policies and new vaccine
introductions. Transition plans attempt to address this issue and
Gavi is currently investing over 30% of its transition resources on
strengthening ‘‘information, data and systems for decision-
making” [24]. Despite this investment, the limited time remaining
for several countries to complete their Gavi transition presents a
considerable risk. Establishing systems that generate reliable data
and institutionalizing fact-based decision-making requires time.
4.2. Political commitment and financial sustainability
Our analysis confirms previous conclusions on immunization
financing. Country performance is difficult to assess without clear
targets, yet transitioning countries encounter identifiable chal-
lenges. In particular, a review of in-country assessments reveals a
lack of skills and processes to develop sound financing and resource
mobilization strategies. Under its Strategic Focus Area of Sustain-
ability, Gavi has committed to investments in financial planning
and resource mobilization. Yet, at present, only 3% of transition
Table 4
Issues identified by area in transition assessments.
Area Sub-area % of Countries with 1+
Issue
Issues identified
Decision-Making (NITAG) – 40%  No NITAG established
 Need for training & peer-to-peer exchange
 Weak surveillance activities & lack of data
Political Commitment and Financial
Sustainability
– 67%  Lack of resource mobilization strategies/capacity
 Lack of economic analysis skills to inform advocacy
 Lack of immunization financing strategy
Demand for and Equitable Delivery of
Vaccines
Data Management 60%  Weak use of available data
 Dysfunctional electronic data systems
 Lack of data quality monitoring
 Need for population census
Communication 80%  Weak social mobilization
 No national immunization communication strategy
development
 Weak use of mass media
Human Resources for
Health
67%  Need for training on logistics and basic immunization
practices
Supply Chain 80%  Lack of equipment or aging of equipment
 Need for training on equipment maintenance and vaccine
management
Access to Timely and Affordable Supply Procurement 73%  Weak forecasting
 No established procurement team
 Weak procurement processes
 Limited procurement experience
 Weak market knowledge
 Weak staff training
 Inappropriate buffer stock
 Insufficient and/or untimely funding
 Exclusive focus on price of procurement
 Customs and port clearance issues
 Inability to conduct multi-year tenders
NRA 53%  Market authorization
 Pharmacovigilance
 Regulatory system
 Lot release
 Laboratory access
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investments are dedicated to supporting countries with inadequate
financial planning or management and budgeting capacity [23].
Moreover, a potential shortfall of the Gavi transition process is that
it tends to focus exclusively on immunization and may thus be
unable to identify system-wide constraints to sustainability nor
integrated and sector-wide approaches to overcome them.
Future challenges in the area of sustainable financing include: i)
matching the concurrent withdrawal of other donors (e.g. the Glo-
bal Fund) with national-level efforts to ensure adequate fiscal
space and financing for the entire health sector; and ii) ensuring
the sustainability of alternative means of support [25,26]. In fact,
despite considerable investments by Gavi for developing and
applying tools to assess immunization financing challenges as well
as for costing immunization programmes, options to help countries
mobilize national resources for immunization are underdeveloped.
Positive experiences from the European and Latin American
regions may prove useful in guiding policy.
4.3. Demand for and equitable delivery of vaccines
The review of vaccine hesitancy, communication for immuniza-
tion, availability of skilled human resources, and effective vaccine
Table 5
Alignment between transition assessment issues and transition plan activities, by programmatic area.
The table provides an overview of the alignment between transition assessments and transition plans for each country. Each column represents a country (n = 13), and each
row indicates an issue. Green: an issue was identified in a transition assessment and was addressed in the transition plan. Yellow: an issue was not explicitly identified in the
assessment but was nonetheless addressed. Red: an issue was identified in the transition assessment but not addressed in the plan. Grey: no issue identified or addressed.
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management reveals critical issues across all assessments. Transi-
tion plans invest important resources to address weaknesses in
these areas, but not consistently (36% of identified challenges don’t
seem to be addressed). Furthermore, available time and resources
may be limited and a complete interruption of external support
may endanger progress. Options to continue providing limited sup-
port to countries should be explored, perhaps through stronger
integration of the immunization sector with the broader health
system and through longer term financial mechanisms, such as
concessional loans. A concern that emerges less clearly from our
review of transition assessments, but which may warrant dedi-
cated attention moving forward, is the consistent discussion of
equity issues and solutions in all countries.
4.4. Access to timely and affordable supply
An appraisal of challenges affecting access to affordable vaccine
supplies provides informative results. In the area of procurement,
concerns have been expressed regarding the ability of countries
to continue procuring through UN agencies following the termina-
tion of Gavi support. Our analysis suggests that this problem may
be limited to a few countries. In these cases, with advocacy to mod-
ify regulatory procedures, immunization partners must support
countries in allowing for regulatory exceptions in the short- to
medium-term.
Of greater concern is a generalized need to strengthen in-
country practices for both UN and self-procurement. Considering
the limited tools and support provided by the international immu-
nization community for procurement, coupled with limited clarity
on the role of different development agencies, this is a significant
finding. Through transition plans, Gavi is only initiating investment
in this area. Additionally, these investments may be too small to
address long-term issues linked to weak pharmaceutical and pro-
curement laws requiring several years and strong political commit-
ment to change.
Finally, vaccine affordability has received significant attention
in transition assessment discussions, with countries flagging
important concerns. Yet, as a result of recent manufacturers’ com-
mitments to affordable prices for Gavi transitioning countries, a
relatively smooth transition should be possible, supported by a
recent analysis [27]. It may be important to ensure available pric-
ing commitments are promptly communicated to countries to ease
anxiety and inform policy making.
While notable differences in performance by geographical
region did not emerge from our results, nor are conclusions possi-
ble given the small available sample of countries, future compara-
tive analyses could review a larger volume of data to better target
investments. So far, results indicate some geographical hetero-
geneity in terms of the main areas of need, confirming the impor-
tance of tailored approaches for each country during the Gavi
transition process. However, within each programme area studied,
countries experience comparable challenges requiring similar
types of support. These results encourage the current timid interest
by development partners to invest in peer platforms to boost learn-
ing and leverage country knowledge and past experience—a sus-
tainable approach to external support following Gavi transition.
In collaboration and consultation with countries, industry, and
civil society organizations, global immunization partners devel-
oped a Middle Income Strategy endorsed by WHO SAGE in April
2015 to address several challenges encountered by MICs never
been eligible for Gavi support. With some variability, challenges
experienced by Gavi transitioning countries are similar [3]. While
the MIC Strategy currently remains largely unfunded, the transi-
tion out of Gavi of several highly populated countries may improve
awareness and interest in this mandate.
5. Conclusion
Middle Income Countries (MICs) losing support from Gavi, the
Vaccine Alliance, require special attention to achieve Global Vac-
cine Action Plan (GVAP) targets. This study examined available lit-
erature and programmatic data for 15 transitioning countries
documenting and beginning to address a gap in systematic analysis
of programmatic performance and challenges. The analysis sug-
gests that the transition period between a Gavi-supported pro-
gramme and a self-sufficient immunization programme
represents a key opportunity for targeted investments to address
shortfalls, but also that a complete interruption of support follow-
ing exit may jeopardize sustainability. Transitioning countries are
struggling across four programmatic areas: decision-making; polit-
ical commitment and financial sustainability; equitable delivery of
vaccines; and access to timely and affordable supply. Continued
monitoring of countries’ performance beyond financing is thus
key to informed policy-making on sustainability of immunization
efforts spurred by external donor support. Development of a
shared theory of change towards sustainable immunization pro-
grammes and a related monitoring and evaluation framework
would allow clearer measurement of progress, gaps, and under-
standing of key areas for future investment.
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